AstraZeneca inaugurates $224M Russian plant; Flu vax makers ship record number of shots in U.S.;

@FiercePharma: Japanese drugmakers Eisai, Ajinomoto team up on gastrointestinal diseases. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Regeneron more than doubles investment in plant in Ireland, adding 200 more workers. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Merck KGaA exits 'sea of sameness' with futuristic rebrand. More | Follow @CarlyHFierce

> AstraZeneca ($AZN) opened a new $224 million plant in Russia, with plans to produce more than half its drugs for the Russian market there by 2017. Report

> Manufacturers are distributing a record number of flu vaccines this year, with up to 179 million doses shipping in the U.S. Report

> Controversy over the pharma-related provisions of the Trans-Pacific Partnership (TPP) could derail the treaty's approval, experts say. Report

> Pharma companies in India--both domestic and multinational--are teaming up to push for ethical marketing practices and to clean up their image. Report

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: Fierce 15 co. Shockwave Medical aims to deploy energy-delivering balloons in the peripheral and coronary arteries. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Lightpoint Medical nabs EU approval for cancer molecular imaging device. Article | Follow @EmilyWFierce

> Stryker scores point in patent battle with Zimmer. More

> Philips spins Axsun back out of Volcano, sells it to venture firm. Story

Biotech News

@FierceBiotech: FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval. Story | Follow @FierceBiotech

@JohnCFierce: Anthony Philippakis at The Broad will be on my JP Morgan Big Data panel. Any other recommendations for Drug Development and Big Data: 2025? | Follow @JohnCFierce

> Actelion says it doesn't need big buyouts as billion-dollar rumors simmer. Report

> Genentech co-signs Nimbus' computer-aided R&D with an oncology pact. Article

> Big science: Upstart Gritstone bags $102M to go after a new immuno-oncology target. More

> Bluebird shares dented after gene therapy patient experiences a setback. Story

Drug Delivery News

> Computer models demonstrate stronger liposomal shells for drug delivery. More

> Researchers deploy malarial protein as targeting agent for anticancer drugs. Report

> Ear drug delivery to get a boost from launch of hearing loss therapeutics company Decibel. Item

> Alnylam reveals molecule to reverse effect of its RNAi therapies. Story

> Novo to expand use of Emisphere's oral delivery platform in deal potentially worth $80M+. Article

Pharma Manufacturing News

> FDA cites Cipla India plant after U.S. recall of asthma drug. News

> Recipharm shelling out $105M for Indian sterile injectables CMO. Report

> Hovione adding a formulation plant in Portugal. More

> TxCell, whose plant was closed for mold issues, intends to use CMOs exclusively. Story

> Regeneron doubles down on plant project in Ireland. Article

Pharma Asia News

> Indian drug manufacturers face higher costs with bar-code requirement. Report

> NY-based Athenex has big China manufacturing plans with name change to boot. Story

> Japan's Daiichi Sankyo to cut as many as 1,200 U.S. jobs in reorganization. Item

> Vietnam's Vinamilk on the block--will Abbott bite? More

> HK-based Chi-Med looks to tap funds in Nasdaq listing with China focus. Article

And Finally... Regulating dopamine levels in the brain can reduce alcohol cravings, a study found. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.